Dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a novel class of anti-diabetic agents confirmed to improve glycemic control and preserve β-cell function in type 2 diabetes. Three major large-scale studies, EXAMINE, SAVOR-TIMI 53, and TECOS, have confirmed the cardiovascular safety profile o...
Dipeptidyl peptidase 4 (DPP4) inhibitors have increasingly been linked to bullous pemphigoid, but there is paucity of data from India where about 1.85 million patients have been estimated to use these drugs.#In 30,000 patients with T2DM seen by us in two tertiary care centres since 2015, we ...
二肽基肽酶-4(Dipeptidyl peptidase-4,DPP-4)抑制剂是一种新型降糖药物,主要通过抑制内源性肠促胰岛素-胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽的降解而起到降血糖的作用。许多研究已证实DPP-4抑制剂对2型糖尿病患者的胰岛β细胞具有保护作用。DPP-4是一种在体内广泛表达的酶,由此推测DPP-4抑制剂是一种多...
The physician has now multiple choices to manage his/her patient after secondary failure of metformin, and the question whether it is preferable to add an oral dipeptidylpeptidase-4 (DPP-4) inhibitor (gliptin) or an injectable glucagon-like peptide-1 (GLP-1) receptor agonist will emerge. ...
Dipeptidyl peptidase (DPP)-4 inhibitors inhibit the activity of the enzyme responsible for the initial rapid degradation of the incretin hormones, thereby enhancing their antihyperglycemic effects.
dipeptidyl peptidase-4 (DPP-4) inhibitorsglucagon-like peptide 1 (GLP-1)incretin hormonessaxagliptinvildagliptinsitagliptinlinagliptinalogliptinThe production of glucagon-like peptide 1 (GLP-1), an incretin hormone, has been shown to be abnormally low in patients with type 2 diabetes, suggesting that ...
Incretin-based therapies, which include the GLP-1 receptor agonists and DPP-4 inhibitors, use the antidiabetic properties of potentiating the GLP-1 receptor signalling via the regulation of insulin and glucagon secretion, inhibition of gastric emptying and suppression of appetite. Most physicians will...
网络抑制剂;二肽基肽酶 网络释义
The dipeptidyl peptidase-4 (DPP-4) inhibitors Sitagliptin and Vildagliptin lower blood glucose by augmenting endogenous levels of glucagon-like peptide-1 (GLP-1), an incretin which also confers cardioprotection. As such, we hypothesized that treatment with DPP-4 inhibitors are also cardioprotective. ...
Post to: Cannotea CiteulikeDel.icio.us Facebook LinkedIn Twitter. Other articles by Dr Jennifer Green. doi:10.2147/dhps.s6270HealthPolicyPharmacologyDove PressDrug